2 Step Process Enables Extraction of Cannabinoids at 99% Purity
Original story from AXIM Biotech
AXIM Biotechnologies has announced the first-ever successful execution of proprietary current good manufacturing practices (“cGMP”) methods to extract and microencapsulate cannabinoid molecules for a variety of pharmaceutical delivery formats from cGMP-produced medicinal cannabis. The breakthrough makes AXIM the only company in the world with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (“APIs”) of such purity from naturally extracted cGMP sources.
AXIM’s new methods are unprecedented in terms of the nature of the process – which utilizes cGMP standards employed from the initial growing of the cannabis plants through extraction and manufacturing – leading to the highest of quality standards for APIs being met.
The process, which was developed and tested in the Netherlands under strict regulatory guidelines, involves the growing of selected cannabis plants at a cGMP facility followed by extraction of the cannabinoid molecules from cannabis flowers in an innovative process that employs just two steps in order to achieve an average of more than 99% purity – unlike traditional methods that include toxic solvents and multiple steps to produce the final extract or synthesize an API such as dronabinol.
AXIM’s newly developed microencapsulation method is then applied to the cannabinoids, protecting those from oxidation and degradation, while preserving its effectiveness. Finally, AXIM’s microencapsulated cannabinoids are manufactured into pharmaceutical products within different delivery formats.
“We’re thrilled to be able to announce this new method to the industry,” said George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM Biotech. “Our innovative extraction process achieves reliable and effective results while providing a high purity level. By microencapsulating these molecules, we are able to protect them and preserve the APIs while increasing their bioavailability and the potential therapeutic benefits for a variety of pharmaceutical applications.”
“At AXIM, we’re committed to best practices and innovation, and the fact that we can apply this new and fully cGMP compliant process to a number of applications is very exciting,” said Anastassov. “We’re confident that our work in developing these cGMP methods, along with our diversified delivery systems and products and on-going research, will expand the pharmaceutical cannabinoid market and broaden the potential areas of application based on specific indications.”